Menu
The AHA raised concerns that October 2024 federal guidance on Medicare drug price negotiations may allow drugmakers to “wrongly justify fundamental changes to the 340B program.”

AHA Urges CMS to Block Drugmaker 340B Rebate Models, Improve Medicare Transaction Facilitator

Bella Czajkowski, National Correspondent 340B Report Views
A major hospital advocacy group recently warned that October 2024 agency guidance on Medicare drug price negotiations may allow drugmakers [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Indiana State Senator Renews Push for 340B Provider Reporting Bill in New Legislative Session

Drugmaker Lawsuit Targets 340B Eligibility of In-Kind STD Clinics; STD Grantee Denies Allegations

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live